What Cartalax is
Cartalax is a synthetic peptide made of three amino acids: alanine, glutamic acid and aspartic acid, written Ala-Glu-Asp or AED. It weighs 333.29 g/mol, and its CAS number is 85806-95-7. In older papers it appears as T-31.
It belongs to the family of short "bioregulator" peptides described by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology.
Their theory is that very short peptides, two to four amino acids long, enter cells and influence gene expression in a tissue-specific way. The name points at the target tissue: Cartalax is the cartilage one.
One source of confusion is worth clearing up. A few sites list Cartalax as Ala-Glu-Asp-Gly. That four-residue sequence is AEDG, better known as Epitalon, a different compound. Cartalax is the tripeptide.
What the published research covers

BioLongevity Labs
Epithalon (20mg)
We searched PubMed for AED, Ala-Glu-Asp and Cartalax on 18 November 2026. Around a dozen indexed papers study AED directly.
Nearly every one comes from Khavinson's institute or lists its researchers as co-authors, and most appeared in two journals: Bulletin of Experimental Biology and Medicine and the Russian-language Advances in Gerontology.
Here is what they test, in plain terms:
- Cartilage cells. In a 2023 cell-culture study, AED raised gene expression and protein synthesis for SOX9, aggrecan, type II collagen and COMP in aging human mesenchymal stem cells pushed toward cartilage. A companion paper reports AED normalising aging-related inflammatory and senescence markers in chondrocytes. Both papers are in Russian with English abstracts.
- Skin fibroblasts. AED increased sirtuin-1, sirtuin-6 and collagen I in aging human skin fibroblasts, and in an earlier study reduced markers of matrix breakdown and cell death.
- Stem-cell gene expression. In a 2020 Molecular Biology Reports paper, AED and two related peptides raised IGF1 and NF-kB gene expression in aging bone-marrow stem cells.
- Kidney. AED nudged proliferation up and cell death down in rat kidney tissue cultures, and lowered urinary protein in rats with drug-induced kidney failure, the only live-animal result for AED we found.
How much weight that evidence can carry
Very little, so far. Put bluntly, the whole case for Cartalax rests on cell and tissue cultures plus one rat study, nearly all produced by the group that developed the peptide.
Cell culture is a reasonable first step, and a long way from a living joint. A compound has to survive the body, reach cartilage, and act at a realistic concentration, and none of that has been tested here.
The studies are also small, rarely report effect sizes in the abstract, and haven't been repeated by an unrelated lab.
The closest thing to outside involvement is a 2019 paper run with an Italian stem-cell lab in Chieti, and even that tested AED alongside three other Khavinson peptides and included Khavinson's team as authors. AED alone didn't move the main neuronal markers in that study; the peptide mixture did.
We found no human trials of Cartalax indexed on PubMed. Much of the bioregulator literature sits in Russian journals and books that PubMed doesn't index, so there may be more out there. We can't assess what we can't read, and neither can most buyers.
Our upcoming guide to bioregulator peptides covers the wider family, including Thymalin, Vesugen and Cortagen.
What Cartalax costs at BioLongevity

BioLongevity Labs
BPC-157 (10mg)
BioLongevity Labs sells Cartalax as a 20mg lyophilised vial and inside its Regeno Blend. Prices read from the store on 18 November 2026, with the 15% ATLAS15 code worked out.
| Product | Contents | Listed | With ATLAS15 | Buy |
|---|---|---|---|---|
| Cartalax (20mg) | 20 mg AED | $69.97 | $59.47 | Shop |
| Regeno Blend (30mg) | 10 mg each: BPC-157, TB-500, Cartalax | $279.97 | $237.97 | Shop |
BioLongevity Labs Cartalax prices, checked 18 November 2026
The Regeno Blend
Regeno pairs Cartalax with two of the most-studied research peptides, BPC-157 and TB-500, at 10 mg each. BioLongevity's page describes the TB-500 in this blend as the full 43-residue thymosin beta-4 sequence, which differs from the short fragment in its separate BPC-157 + TB-500 blend. Our BPC-157 vs TB-500 comparison explains why that distinction matters.
Its certificate (BioRegen, #11988, January 2026) confirms all three identities at 99.5% to 99.7% purity.
The quantities are another matter. It measured 15.2 mg of BPC-157, 16 mg of thymosin beta-4 and 24.62 mg of Cartalax against a 10 mg specification for each, and the lab flagged the Cartalax figure "Over-Conforming". Two of the three pages list no lot number.
Overfill says nothing about safety. What it changes is the ratio. A vial labelled 10:10:10 that tests closer to 15:16:25 will throw off any concentration worked out from the label. If you're running the numbers through our peptide calculator, ask BioLongevity for the COA for your own lot first.
The Cartalax COA, checked
BioLongevity publishes its certificates in an open COA Library, no account needed. That matters here because some of its published certificates have had template errors, including an LL-37 certificate labelled Cardiogen. So we opened the Cartalax one and read it.
It matches. The certificate from MDx BioAnalytical Laboratory (search code 251575) names the product as Cartalax, 20 mg, and reports 20.67 mg measured at 99.7% purity. Its mass spectrum shows a main peak at 334.18, which is what you'd expect for a 333.29 g/mol molecule carrying one extra proton.
One small oddity: the "reported date" reads 06 Nov 2027, a year after the 05 Nov 2025 received date, which looks like a typo.
A separate BioRegen endotoxin report (lot 35-3-45958, November 2025) shows below 0.050 EU/mL, a pass against its 0.25 EU/mL limit. Neither certificate is guaranteed to cover the vial you receive, so request the one for your lot. Our guide to vetting a peptide vendor covers what else to check.
Buying, storing and the research-use line
Cartalax is sold for laboratory research only. The FDA hasn't approved it as a drug, it can't legally be sold as a dietary supplement, and we don't give personal dosing guidance. The papers above used it in cell culture at nanogram-per-millilitre concentrations, which doesn't translate into a human amount.
If you're ordering for research, buy from biolongevitylabs.com directly, since lookalike domains trade on the name. ATLAS15 takes 15% off, free shipping starts at $400, and our BioLongevity Labs review sets out what we verified about the company.
If you're comparing it against other vendors, start with where to buy research peptides. If you're adding other compounds to the same order, our LL-37 guide and Epitalon guide cover two more.
BioLongevity says to keep the dry powder at -20°C, away from light, and to refrigerate at 2 to 8°C after reconstitution and use it promptly. The peptide storage guide explains why freeze-thaw cycles are the thing to avoid.

